MedPath

Comparison of effectiveness of Bupropion and Nicotine gum for smokers dependent on Opioids

Phase 4
Conditions
Health Condition 1: F172- Nicotine dependence
Registration Number
CTRI/2024/05/067468
Lead Sponsor
ational Drug Dependent Treatment Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Age 18 to 60 years

Male

Current (last 1 month) user of tobacco by smoking route

Diagnosed with nicotine dependence, current use as per ICD-11 criteria

Currently following up in NDDTC OPD for Opioid agonist maintenance treatment (Buprenorphine-Naloxone) with 80% medication dispensing

Willing to participate in follow up at 4-6 weeks and 12-14 weeks

Exclusion Criteria

History of co-morbid psychiatric illnesses (as per clinical interview)

Current (last 1 month)Dependence on drugs other than opioid and nicotine

Current users of smokeless tobacco

Has ever received tobacco cessation intervention (except simple advice from a health care professional) in the past 3 months

Unwilling to give informed consent

Contraindication for Nicotine replacement therapy (accelerated hypertension, post-myocardial infarction period (2 weeks), hypersensitivity to NRT) or Bupropion (Seizure episode, eating disorder)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
i. Biochemically confirmed seven-day point prevalence abstinence at 1- and 3-month follow-up <br/ ><br>ii. Reduction in smoking use as measured by self-reported amount of tobacco use(number of beedi or cigarettes) <br/ ><br>Timepoint: 1 month and 3 months
Secondary Outcome Measures
NameTimeMethod
i. Continuous abstinence from smoking at 1- and 3-month follow-up (Complete abstinence beginning on the target quit date till the date of assessment) <br/ ><br>ii. Change in the stage of motivation <br/ ><br>Timepoint: 1 month and 3 months
© Copyright 2025. All Rights Reserved by MedPath